

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Factors that Influence Clinicians' Decisions to Decrease Active Surveillance Monitoring Frequency or Transition to Watchful Waiting for Localized Prostate Cancer: A Qualitative Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048347
Article Type:	Original research
Date Submitted by the Author:	18-Jan-2021
Complete List of Authors:	Lowenstein, Lisa; The University of Texas MD Anderson Cancer Center Division of Cancer Prevention and Population Sciences, Health Services Research Choi, Noah; The University of Texas MD Anderson Cancer Center Division of Cancer Prevention and Population Sciences, Health Services Research Hoffman, Karen; MD Anderson Division of Radiation Oncology, Radiation Oncology Volk, Robert; The University of Texas MD Anderson Cancer Center Division of Cancer Prevention and Population Sciences, Health Services Research Loeb, Stacy; New York University, Urology, Population Health
Keywords:	Urological tumours < ONCOLOGY, GENITOURINARY MEDICINE, GERIATRIC MEDICINE, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, QUALITATIVE RESEARCH

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Factors that Influence Clinicians' Decisions to Decrease Active Surveillance Monitoring**  
4  
5  
6 **Frequency or Transition to Watchful Waiting for Localized Prostate Cancer: A Qualitative**  
7  
8 **Study**  
9

10  
11  
12  
13 **Short Title: Decisions about Transitioning to Watchful Waiting for Prostate Cancer**  
14

15  
16  
17  
18 Lisa M. Lowenstein, PhD, MPH<sup>a</sup>  
19

20 Noah J. Choi<sup>a</sup>  
21

22 Karen E. Hoffman, MD, MPH<sup>b</sup>  
23

24 Robert J. Volk, PhD<sup>a</sup>  
25

26 Stacy Loeb, MD, MSc<sup>c, d, e</sup>  
27

28  
29  
30  
31  
32 <sup>a</sup> Department of Health Services Research, The University of Texas MD Anderson Cancer Center,  
33 1400 Pressler Street, Unit 1444, Houston, TX 77230, USA.  
34

35  
36  
37 <sup>b</sup> Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center  
38

39  
40 <sup>c</sup> Department of Urology, New York University, New York City, USA  
41

42 <sup>d</sup> Department of Population Health, New York University, New York City, USA  
43

44 <sup>e</sup> Manhattan Veterans Affairs Medical Center, New York City, USA  
45

46  
47  
48  
49 **Corresponding Author:**  
50

51 Lisa M. Lowenstein, PhD, MPH  
52

53 Department of Health Services Research  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The University of Texas MD Anderson Cancer Center

4  
5  
6 1400 Pressler Street, Unit 1444

7  
8 Houston, TX 77230

9  
10 Phone: 713-792-5807

11  
12  
13 Fax: 713-563-0059

14  
15 Email: [LMLowenstein@mdanderson.org](mailto:LMLowenstein@mdanderson.org)

16  
17  
18  
19  
20 **Keywords:** Active Surveillance; Cancer; Observational Study; Oncology, Prostatic Neoplasms;

21  
22  
23 Qualitative Evaluation; Treatment Adherence and Compliance

## ABSTRACT

**Objective:** Little is known about clinicians' decision-making about decreasing active surveillance (AS) testing/converting patients to watchful waiting (WW). The objective of this study was to identify factors that clinicians consider when decreasing surveillance testing or transitioning to WW.

**Design:** Exploratory study using a qualitative approach.

**Setting:** All participants interviewed in this study practiced in various institutions in the U.S.

**Participants:** Eligible clinicians had to provide clinical care for patients with prostate cancer in the U.S. and speak English. Clinicians could be either urologists or radiation oncologists. Of the 24 clinicians, 83% were urologists representing 11 states, 92% were male, and 62% were White.

**Methods:** This qualitative study used data from semi-structured interviews with clinicians who monitor men on AS. Purposive sampling was used to ensure geographic variation in the U.S. Data collection continued until thematic saturation was achieved. Framework analysis guided coding and identification of themes. Two researchers coded all transcripts independently, met to discuss, and reached consensus.

**Results:** Interviews with clinicians demonstrated that testing or monitoring for AS or transitioning to WW is happening in practice, whether intentionally or unintentionally. Decisions to decrease AS were personalized and tailored to patients' health status. Life expectancy was the dominant factor that influenced decision, but clinicians were generally hesitant to specify an age when they would decrease AS or transition to WW. Fear that poor adherence could lead to missed progression and concerns about the medical legal issue of not doing enough were cited as barriers to decreasing AS.

1  
2  
3 **Conclusions:** These findings suggest that AS test frequency is being reduced and men are being  
4 transitioned to WW in clinical practice, yet decisions appear to be inconsistent and there are no  
5 significant barriers. Recommendations are needed to guide decisions about converting to WW  
6 that explicitly consider patients values and preferences.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Strengths and Limitations of this study:**

- Qualitative study to explore clinicians' decision making about decreasing or transitioning men with prostate cancer on active surveillance.
- Semi-structured interviews with clinicians from different regions of the United States from academic centers and Veterans Affairs hospitals.

For peer review only



## BACKGROUND

PSA based screening reduces diagnosis of advanced prostate cancer but results in more men diagnosed with low-risk disease. In the Cancer of the Prostate Strategic urological Research Endeavor (CaPSURE), the prevalence of men diagnosed with low-risk disease increased from 14.8% in 1990 to 47.7% in 2013.<sup>1</sup> Data from the US Cancer Statistics 2005-2016 Public Use Research Database, suggest that the proportion of localized prostate cancer decreased from 88.1% to 80.5%.<sup>2</sup>

Low-risk disease is unlikely to cause symptoms or affect survival if left untreated. In contrast, unnecessary treatment may lead to treatment induced urinary dysfunction, rectal bleeding, and impotence.<sup>3</sup> As a result, overtreatment remains a major concern, with estimates ranging between 6% to 64%.<sup>4</sup> In response, clinical guidelines recommend active surveillance as the preferred management for patients with low-risk disease to minimize overtreatment.<sup>5,6</sup>

The decision to place a man on active surveillance for prostate cancer is often based upon clinical characteristics of the disease and life expectancy.<sup>7</sup> The National Comprehensive Cancer Network recommends active surveillance as the preferred management strategy for men with at least 10 years of life expectancy if they have low-risk disease; whereas, observation is recommended for those with life expectancy <10 years.<sup>6</sup> The American Urological Association, American Society of Radiation Oncology, and the Society of Urologic Oncology recommends active surveillance for men when they have a life expectancy of five years or more.<sup>5</sup> There is

1  
2  
3 some guidance on the frequency and modality of testing, but there is a significant amount of  
4  
5  
6 variability in practice.<sup>7,8</sup>  
7  
8  
9

10 Although there is guidance about when to start active surveillance, discussion or literature on  
11  
12 what clinicians consider or have experienced when decreasing the frequency of testing for  
13  
14 active surveillance and/or transitioning to watchful waiting is largely absent. A consensus  
15  
16 statement from the United Kingdom does state that the decision to convert to watchful waiting  
17  
18 should consider men's preferences, clinical characteristics, comorbidities, functional  
19  
20 impairment, and life expectancy.<sup>9</sup> The purpose of this study was to identify factors clinicians  
21  
22 consider when decreasing surveillance testing frequency or converting to watchful waiting for  
23  
24 prostate cancer.  
25  
26  
27  
28  
29  
30

## 31 32 **METHODS**

### 33 34 **Study Design**

35  
36 This study used data from a previously published qualitative study of clinicians that care for  
37  
38 patients with prostate cancer.<sup>10</sup> Eligible clinicians had to provide clinical care for patients with  
39  
40 prostate cancer in the United States and speak English. Clinicians could be either urologists or  
41  
42 radiation oncologists. All participants provided written informed consent and completed an  
43  
44 intake questionnaire prior to their interview. The institutional review board approved this study  
45  
46  
47  
48 (NYU: i14-02147; MD Anderson PA17-0642, exempt).  
49  
50  
51

### 52 53 54 **Recruitment**

1  
2  
3 Loeb and colleagues used a combination of purposive sampling to select urologists from both  
4  
5 the American Urological Association and the American Society of Clinical Oncology  
6  
7 memberships and snowball sampling.<sup>10</sup> Purposive sampling ensured that each clinician was  
8  
9 experienced with providing active surveillance care and were from geographically diverse  
10  
11 settings across the United States. Eligible clinicians who were informed about the study were  
12  
13 allowed to nominate other colleagues as potential participants as long as they also met  
14  
15 eligibility criteria. Participants were contacted by email, and were given the choice to have their  
16  
17 interview either in person, or over the phone.  
18  
19  
20  
21  
22  
23  
24

### 25 **Data Collection and Management**

26  
27 All interviews were conducted from July to December of 2015. Data collection procedures were  
28  
29 described previously.<sup>10</sup> In brief, that study initially conducted 17 interviews, and then  
30  
31 conducted seven more interviews to reach thematic saturation. Interviews were conducted  
32  
33 with the study participants only and lasted between 22 to 51 minutes. Atlas.ti was used to  
34  
35 facilitate data management and analysis.  
36  
37  
38  
39  
40  
41  
42

### 43 **Interview**

44  
45 The interviewers used an interview guide that was developed from a literature review and  
46  
47 previous active surveillance research. The guide consisted of fifteen questions, including “What  
48  
49 are your triggers to stop active surveillance and convert to watchful waiting?” and “What are  
50  
51 your main concerns about active surveillance?” All interviews were audio recorded and  
52  
53 anonymously transcribed by a third-party service.  
54  
55  
56  
57  
58  
59  
60

## Analysis

For this study, framework analysis guided our analytical approach.<sup>11,12</sup> Two researchers independently reviewed each transcript to develop codes and met to discuss the codes. As coding progressed, researchers met and discussed how to organize and conceptualize the coded text. We charted the coded text into matrices to facilitate identification of themes.

## Patient and Public Involvement

No patient involvement.

## RESULTS

### Sample characteristics

A total of 24 of 48 clinicians participated in the interviews. The characteristics of the participants were published previously.<sup>10</sup> Majority of the clinicians were urologists (n=20), male (n=22), and White (n=15) and represented 11 states.

### Overview of qualitative findings

From these interviews, we found that the frequency of surveillance testing is being reduced and patients are being transitioned to watchful waiting, whether intentionally or unintentionally.

Life expectancy considering age and existing comorbidities was the dominant factor influencing these decisions. However, there were some barriers to decreasing test frequency and transitioning to watchful waiting. One barrier is the concern of poor adherence leading to missed disease progression. They also discussed the fear of being potentially sued.

*Reduced Testing and Converting to Watchful Waiting is Happening in Practice*

Patients and/or clinicians are reducing the frequency of surveillance testing, whether unintentionally or intentionally. The surveillance testing frequency may be spread out due to patients missing or cancelling appointments. Reasons could include the general discomfort with the biopsy procedure and/or issues with transportation. They also noted that the appointments take time, which interferes with their work.

*“Because not just with these patients but every patient has to come to the office every three months, take time off work or you know, wait in the office. I think that really bugs them.”*

Clinician 19

One clinician mentioned how there isn't really a trigger to switch to watchful waiting, unless patients stops showing up.

*“Yes if you mean by watchful waiting we don't see the people or the individuals anymore or perform any other tests on them then I would say we don't ever convert someone to watchful waiting unless they can't make it back for a visit.”* Clinician 14

Clinicians discussed situations where the patients have wanted to switch to watchful waiting because they have not progressed for many years.

1  
2  
3 *"[...] he actually went through like five years of yearly consecutive biopsies where his PSA*  
4 *didn't change much, his DRE is the same. The pathology was nothing or one or two core*  
5 *right. And, you know, alternating, you know, nothing or a little something. And after year*  
6 *five he was like I'm done, you know, no more we're done. I'm like you know what if I were*  
7 *you I would do the same thing."* Clinician 07  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17

### 18 *The role of life expectancy, age, and comorbidities*

19  
20 Life expectancy, considering age and comorbidities, was the primary factor that influenced  
21 decisions to reduce surveillance testing and/or transition to watchful waiting. The decision to  
22 space out testing required clinicians to balance a patient's risk of dying from prostate cancer  
23 compared to their other comorbidities, and how the patient values its impact on quality of life  
24 and potential for benefit.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 *"Well, whenever I see a patient, we're always thinking about based on what we know about*  
36 *this patient now, what's their risk of dying of prostate cancer, and then what's their risk of*  
37 *dying of other disease? And finally, how do they value their quality of life?"* Clinician 18  
38  
39  
40  
41  
42  
43  
44

45 It was clear that clinicians tailor their decisions about transitioning to watchful waiting based on  
46 patients' health status.  
47  
48  
49  
50  
51

52 *"I mean, there's two different scenarios. One scenario is you've watched someone for a*  
53 *while; maybe you've gotten biopsies on them. Their PSA has remained stable, and now*  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 *you know, instead of being in the early seventies, now they're in their late seventies or*  
4 *early eighties, and so I think it's reasonable to convert that person to an observation...*  
5  
6 *On the other hand, I think that there are some patients that you can look at very quickly*  
7 *and see this is a patient who's not going to benefit from repeat biopsy or close*  
8 *monitoring because they have too many other medical issues that they're dealing with."*  
9  
10  
11  
12  
13  
14

15 Clinician 03  
16  
17  
18  
19

20 In general, clinicians were reticent to specify an exact age where they would consistently  
21 transition to watchful waiting. One clinician noted the need for a guideline to guide this  
22 decision.  
23  
24  
25  
26  
27  
28  
29

30 *"But I would think like after the age of 80, you know, we could probably just stop*  
31 *because you know, you and I know that you know, most men already are going to have*  
32 *prostate cancer. Most men over 70 will have some cancer cells in them. But I would need*  
33 *some kind of guideline or something somewhere."* Clinician 19  
34  
35  
36  
37  
38  
39  
40  
41

42 However, one clinician felt that 75 years should be the cut-off and will only keep patients on AS  
43 if they insist.  
44  
45  
46  
47  
48  
49

50 *"I would say if someone is on it for 6 years, has gone through our protocol and now*  
51 *they're over 75 years of age then I'll move to, I'll go to watchful waiting... I tell them if*  
52 *you came to me with a normal PSA and a normal rectal exam since age 75 I would stop*  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 following you at age 75. Sometimes I'll go to 80 if they're really healthy and they're  
4  
5 insisting on it but most patients I try to encourage them to say listen we've made it to 75  
6  
7 without a problem it's reasonable to just not check it." Clinician 09  
8  
9

### 10 11 12 *Barriers to decrease testing and transitioning to watchful waiting*

13  
14 Concerns about poor adherence leading to missed disease progression. One barrier to  
15  
16 decreasing test frequency or transitioning to watchful waiting was clinicians' concern about  
17  
18 poor adherence, resulting in missing disease progression. One clinician had a patient who did  
19  
20 not adhere to the active surveillance schedule and came back and had progressed.  
21  
22  
23  
24  
25  
26

27  
28 *"Cause if you've got a patient that should come back in six months and they kind of fall off*  
29  
30 *the radar, then there's a chance that there are patients out there -- by the way, this*  
31  
32 *happened a couple times where patients come back a year and a half later and they've had*  
33  
34 *progression... that if patients aren't compliant, then active surveillance doesn't work."*  
35  
36

37 Clinician 06  
38  
39  
40  
41

42 Fear of litigation/retribution. Clinicians expressed that fear of legal action is in the back of their  
43  
44 mind, but acknowledged that it is rare that they are sued.  
45  
46  
47  
48

49  
50 *"The third barrier is worry over legal stuff although I've never heard of someone being sued*  
51  
52 *because of surveillance or not but I think that's in the back of people's minds. When I talk to*  
53  
54 *private practice guys they say that".* Clinician 12  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6 The fear of litigation is further amplified by the misalignment of active surveillance and the  
7  
8 natural context of the field and purpose of their work.  
9

10  
11  
12  
13 *“Well there is misalignment of how should I say let’s say perverse incentives for managing*  
14  
15 *people with low grade disease. In other words, physicians get reimbursed for doing*  
16  
17 *something not for doing nothing.”* Clinician 14  
18  
19  
20  
21  
22

## 23 **DISCUSSION**

24  
25 Our qualitative analysis found that surveillance testing for prostate cancer is being decreased  
26  
27 and/or transitioned to watchful waiting in clinical practice. Intentional decisions to decrease  
28  
29 surveillance testing/transition to watchful waiting consider patients’ age, health, and life  
30  
31 expectancy. These decisions may also take into consideration patients’ values and preferences.  
32  
33 Unintentional decisions to decrease surveillance testing/transition to watchful waiting are due  
34  
35 to poor adherence to missed or cancelled appointments. These missed appointments may be  
36  
37 an indicator that patients are prioritizing their quality of life or ability to work over the  
38  
39 management of their prostate cancer.  
40  
41  
42  
43  
44  
45  
46

47 The influence of age, health, and life expectancy has been noted in other studies examining  
48  
49 clinician’s decision making about starting active surveillance<sup>13</sup> and is incorporated in  
50  
51 guidelines.<sup>14</sup> In contrast, a study where clinicians were presented with scenarios and rank  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 ordered factors that influenced their decision making about starting active surveillance, found  
4  
5 that clinicians used 10-year survival probability, stage, and PSA.<sup>15</sup>  
6  
7  
8  
9

10 A modeling study demonstrated that generally active surveillance had greater quality adjusted  
11  
12 life years than watchful waiting, except among patients diagnosed older than 65 years.<sup>16</sup>  
13  
14

15 Another study found that for men older than 65 years, one biopsy round resulted in a loss of  
16  
17 one quality adjusted life year, likely due to other quality of life outcomes and potential biopsy-  
18  
19 related complications.<sup>17</sup> The University of Toronto stops serial biopsies once a man is 80 years  
20  
21 old and has a life expectancy of less than five years.<sup>18</sup> However, the consensus statement from  
22  
23 the United Kingdom does state that age as well as other factors need to be considered,  
24  
25 including frailty.<sup>9</sup>  
26  
27  
28  
29  
30  
31

32 As time on active surveillance increases, clinicians' and patients' comfort with the idea that they  
33  
34 are unlikely to progress may support them in making the decision to decrease the frequency of  
35  
36 surveillance testing/transition to watchful waiting. This finding is consistent with the literature  
37  
38 around men who select active surveillance. Patients and their families who may be more  
39  
40 anxious are less likely to choose active surveillance initially or stop active surveillance for  
41  
42 immediate treatment.<sup>13,19</sup> One qualitative study found that men on active surveillance  
43  
44 understood their disease was low-risk and were confident there would be time for curative  
45  
46 treatment if they progressed. These men also had to convince family members that they were  
47  
48 not crazy for having a cancer and not treating it immediately.<sup>20</sup>  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The issue of adherence is also associated with the fear of missing the window of curability.

4  
5 Clinicians noted that active surveillance only works if patients show up for the appointments.

6  
7 However, they recognized that there are practical barriers (e.g., transportation issues and time

8  
9 off from work) that may contribute to nonadherence to the active surveillance protocol. In a

10  
11 large cohort of men with grade group 1 prostate cancer, about 24% were lost to follow-up

12  
13 among men who were not reclassified.<sup>21</sup> However, the increased use of telemedicine due to the

14  
15 COVID-19 pandemic may help with some of the practical barriers in the future.

16  
17  
18 Finally, the fear of litigation may be a barrier to decreasing testing for disease progression and

19  
20 transitioning to watchful waiting. The fear of litigation is likely related to the fear of missing a

21  
22 cancer that will become metastatic and its downstream consequences, such as patients and

23  
24 family members being upset and wanting to sue or submit a complaint.

25  
26  
27 Although this study provides new information regarding what clinicians consider when making

28  
29 the decision to decrease the frequency of surveillance monitoring or to transition to watchful

30  
31 waiting, limitations need to be considered when interpreting the results. The sample consisted

32  
33 of clinicians at academic and Veterans Affairs hospitals. Their perspectives and the patients

34  
35 they treat may not represent the wider group of clinicians who see and treat men with prostate

36  
37 cancer, such as general urologists and primary care providers. Some of the interviews were

38  
39 conducted by a female urologist who is well known among the medical community, which may

40  
41 have introduced response bias. However, this interviewer used open-ended and non-

42  
43 judgmental questioning to facilitate an open-dialogue. The interviewers did not participate in

1  
2  
3 the analysis process for this study, limiting the ability to incorporate the insights of the  
4  
5 interviewers in the analysis process. The results and interpretation of this analysis was shared  
6  
7 and discussed with the primary study lead and interviewer.  
8  
9

10  
11  
12  
13 These findings suggested that surveillance testing frequency is being decreased and patients  
14  
15 are being transitioned to watchful waiting, either intentionally or unintentionally. These  
16  
17 decisions are preference-sensitive and patients' values and priorities in addition to their health  
18  
19 status needs to be considered. Interventions to support shared decision making may be helpful  
20  
21 to identify patients' values and goals of care in making the decision to transition to watchful  
22  
23 waiting. Clinicians and men need guidance to make thoughtful decisions to decrease  
24  
25 surveillance testing or transition to watchful waiting. These guidelines could also emphasize the  
26  
27 need to consider men's preferences in addition to clinical characteristics and encourage shared  
28  
29 decision making.  
30  
31  
32  
33  
34  
35  
36

### 37 **Contributorship statement**

38  
39 Study conception and design: LML; drafting of the study protocol: LML; obtaining of research  
40  
41 funding: LML and SL; acquisition of data: SL. performing of qualitative analysis: LML and NJC  
42  
43 drafting, editing and preparing of the final version of the manuscript: LML, NJC, and SL; Critical  
44  
45 feedback and additional edits: NJC, RJV, KEH, and SL. All authors approved the final manuscript.  
46  
47  
48  
49  
50

### 51 **Funding**

52  
53 Financial Support: This work was supported by a grant from The University of Texas MD  
54  
55 Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment  
56  
57  
58  
59  
60

1  
2  
3 (Shared Decision Making Collaborative) and a grant from NIH/NCI under award number  
4  
5 P30CA016672 (Clinical Protocol and Data Management, and Shared Decision Making Core). Dr.  
6  
7 Lowenstein was supported by the American Cancer Society under Award Number MRS-18-  
8  
9 225-01-CPPB. Additionally, this work was supported through the Prostate Cancer Foundation,  
10  
11 225-01-CPPB. Additionally, this work was supported through the Prostate Cancer Foundation,  
12  
13 Feldstein Medical Foundation, Edward Blank and Sharon Cosloy-Blank Family Foundation, the  
14  
15 Gertrude and Louis Feil Family, the New York Department of Health (DOH01-C30697GG-  
16  
17 3450000), The Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center  
18  
19 (P30CA016087), and the NIH (Award Number K07CA178258) to Dr.Loeb. The content is solely  
20  
21 the responsibility of the authors and does not represent the official views of the NIH.  
22  
23  
24  
25

### 26 **Data Sharing Statement**

27  
28 Research data are not shared.  
29  
30

### 31 **Competing Interests**

32  
33 The authors have no competing interests to report.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. *JAMA*. 2015;314(1):80-82.
2. Jemal A, Culp MB, Ma J, Islami F, Fedewa SA. Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening. *JNCI: Journal of the National Cancer Institute*. 2020.
3. Hoffman RM, Lobo T, Van Den Eeden SK, et al. Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer. *Med Decis Making*. 2019;39(8):962-974.
4. Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. *Eur Urol*. 2014;65(6):1046-1055.
5. Sanda MG, Chen RC, Crispino T, et al. *Clinically localized prostate cancer: AUA/ASTRO/SUO guideline*. 2017.
6. Carroll PR, Parsons JK, Andriole G, et al. NCCN guidelines insights: prostate cancer early detection, version 2.2016. *J Natl Compr Canc Netw*. 2016;14(5):509-519.
7. Bruinsma SM, Bangma CH, Carroll PR, et al. Active surveillance for prostate cancer: a narrative review of clinical guidelines. *Nat Rev Urol*. 2016;13(3):151-167.
8. Lowenstein LM, Basourakos SP, Williams MD, et al. Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned. *Nat Rev Clin Oncol*. 2019;16(3):168-184.
9. Merriel SWD, Hetherington L, Seggie A, et al. Best practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement. *BJU International*. 2019;124(1):47-54.

10. Loeb S, Curnyn C, Fagerlin A, et al. Qualitative study on decision-making by prostate cancer physicians during active surveillance. *BJU International*. 2017;120(1):32-39.
11. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: Bryman A, Burgess RG, eds. *Analyzing Qualitative Data*. London: Routledge; 1994:172-194.
12. Ritchie J, Spencer L, O'Connor W. Carrying out qualitative analysis. In: Ritchie J, Lewis J, eds. *Qualitative Research Practice: A Guide for Social Science Students and Researchers*. London: Sage; 2003:219-262.
13. Pang K, Fitch M, Ouellet V, et al. Describing perspectives of health care professionals on active surveillance for the management of prostate cancer. *BMC Health Serv Res*. 2018;18(1):430-430.
14. Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate Cancer, Version 1.2016. *J Natl Compr Canc Netw*. 2016;14(1):19-30.
15. Clarke MG, Wilson JRM, Kennedy KP, MacDonagh RP. Clinical Judgment Analysis of the Parameters Used by Consultant Urologists in the Management of Prostate Cancer. *Journal of Urology*. 2007;178(1):98-102.
16. Loeb S, Zhou Q, Siebert U, et al. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. *European Urology*. 2017.
17. de Carvalho TM, Heijnsdijk EAM, de Koning HJ. When should active surveillance for prostate cancer stop if no progression is detected? *The Prostate*. 2017;77(9):962-969.
18. Garisto JD, Klotz L. Active Surveillance for Prostate Cancer: How to Do It Right. *Oncology (Williston Park)*. 2017;31(5):333-340, 345.

- 1  
2  
3 19. Berger ZD, Yeh JC, Carter HB, Pollack CE. Characteristics and experiences of patients  
4 with localized prostate cancer who left an active surveillance program. *Patient.*  
5  
6 2014;7(4):427-436.  
7  
8  
9  
10 20. Volk RJ, McFall SL, Cantor SB, et al. 'It's not like you just had a heart attack': decision-  
11 making about active surveillance by men with localized prostate cancer.  
12  
13 *Psychooncology.* 2014;23(4):467-472.  
14  
15  
16 21. Tosoian JJ, Mamawala M, Epstein JI, et al. Active Surveillance of Grade Group 1 Prostate  
17 Cancer: Long-term Outcomes from a Large Prospective Cohort. *European Urology.* 2020.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist

No	Item	Guide questions/description	Page
<b>Domain 1: Research team and reflexivity</b>			
Personal Characteristics			
1.	Interviewer/facilitator	Which author/s conducted the interview or focus group?	16
2.	Credentials	What were the researcher's credentials? <i>E.g. PhD, MD</i>	1
3.	Occupation	What was their occupation at the time of the study?	1
4.	Gender	Was the researcher male or female?	16
5.	Experience and training	What experience or training did the researcher have?	1
Relationship with participants			
6.	Relationship established	Was a relationship established prior to study commencement?	16
7.	Participant knowledge of the interviewer	What did the participants know about the researcher? <i>e.g. personal goals, reasons for doing the research</i>	16
8.	Interviewer characteristics	What characteristics were reported about the interviewer/facilitator? <i>e.g. Bias, assumptions, reasons and interests in the research topic</i>	16
<b>Domain 2: study design</b>			
Theoretical framework			
9.	Methodological orientation and Theory	What methodological orientation was stated to underpin the study? <i>e.g. grounded theory, discourse analysis, ethnography, phenomenology, content analysis</i>	7

No	Item	Guide questions/description	Page
Participant selection			
10.	Sampling	How were participants selected? <i>e.g. purposive, convenience, consecutive, snowball</i>	8
11.	Method of approach	How were participants approached? <i>e.g. face-to-face, telephone, mail, email</i>	8
12.	Sample size	How many participants were in the study?	8
13.	Non-participation	How many people refused to participate or dropped out? Reasons?	9
Setting			
14.	Setting of data collection	Where was the data collected? <i>e.g. home, clinic, workplace</i>	8
15.	Presence of non-participants	Was anyone else present besides the participants and researchers?	8
16.	Description of sample	What are the important characteristics of the sample? <i>e.g. demographic data, date</i>	7
Data collection			
17.	Interview guide	Were questions, prompts, guides provided by the authors? Was it pilot tested?	8
18.	Repeat interviews	Were repeat interviews carried out? If yes, how many?	8
19.	Audio/visual recording	Did the research use audio or visual recording to collect the data?	8
20.	Field notes	Were field notes made during and/or after the interview or focus group?	NR
21.	Duration	What was the duration of the interviews or focus group?	8

No	Item	Guide questions/description	Page
22.	Data saturation	Was data saturation discussed?	8
23.	Transcripts returned	Were transcripts returned to participants for comment and/or correction?	NR
<b>Domain 3: analysis and findings</b>			
Data analysis			
24.	Number of data coders	How many data coders coded the data?	9
25.	Description of the coding tree	Did authors provide a description of the coding tree?	NR
26.	Derivation of themes	Were themes identified in advance or derived from the data?	9
27.	Software	What software, if applicable, was used to manage the data?	8
28.	Participant checking	Did participants provide feedback on the findings?	NR
Reporting			
29.	Quotations presented	Were participant quotations presented to illustrate the themes / findings? Was each quotation identified? e.g. <i>participant number</i>	10
30.	Data and findings consistent	Was there consistency between the data presented and the findings?	10
31.	Clarity of major themes	Were major themes clearly presented in the findings?	9
32.	Clarity of minor themes	Is there a description of diverse cases or discussion of minor themes?	10

# BMJ Open

## Factors that Influence Clinicians' Decisions to Decrease Active Surveillance Monitoring Frequency or Transition to Watchful Waiting for Localized Prostate Cancer: A Qualitative Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048347.R1
Article Type:	Original research
Date Submitted by the Author:	17-Jun-2021
Complete List of Authors:	Lowenstein, Lisa; The University of Texas MD Anderson Cancer Center Division of Cancer Prevention and Population Sciences, Health Services Research Choi, Noah; The University of Texas MD Anderson Cancer Center Division of Cancer Prevention and Population Sciences, Health Services Research Hoffman, Karen; MD Anderson Division of Radiation Oncology, Radiation Oncology Volk, Robert; The University of Texas MD Anderson Cancer Center Division of Cancer Prevention and Population Sciences, Health Services Research Loeb, Stacy; New York University, Urology, Population Health
<b>Primary Subject Heading</b>:	Health services research
Secondary Subject Heading:	Qualitative research
Keywords:	Urological tumours < ONCOLOGY, GENITOURINARY MEDICINE, GERIATRIC MEDICINE, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, QUALITATIVE RESEARCH

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Factors that Influence Clinicians' Decisions to Decrease Active Surveillance Monitoring**  
4  
5  
6 **Frequency or Transition to Watchful Waiting for Localized Prostate Cancer: A Qualitative**  
7  
8 **Study**  
9

10  
11  
12  
13 **Short Title: Decisions about Transitioning to Watchful Waiting for Prostate Cancer**  
14

15  
16  
17  
18 Lisa M. Lowenstein, PhD, MPH<sup>a</sup>  
19

20 Noah J. Choi<sup>a</sup>  
21

22 Karen E. Hoffman, MD, MPH<sup>b</sup>  
23

24 Robert J. Volk, PhD<sup>a</sup>  
25

26 Stacy Loeb, MD, MSc<sup>c, d, e</sup>  
27  
28  
29  
30  
31

32 <sup>a</sup> Department of Health Services Research, The University of Texas MD Anderson Cancer Center,  
33 1400 Pressler Street, Unit 1444, Houston, TX 77230, USA.  
34

35 <sup>b</sup> Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center  
36

37 <sup>c</sup> Department of Urology, New York University, New York City, USA  
38

39 <sup>d</sup> Department of Population Health, New York University, New York City, USA  
40

41 <sup>e</sup> Manhattan Veterans Affairs Medical Center, New York City, USA  
42  
43  
44

45  
46  
47  
48  
49 **Corresponding Author:**

50  
51  
52 Lisa M. Lowenstein, PhD, MPH  
53

54 Department of Health Services Research  
55  
56  
57  
58  
59  
60

1  
2  
3 The University of Texas MD Anderson Cancer Center

4  
5  
6 1400 Pressler Street, Unit 1444

7  
8 Houston, TX 77230

9  
10 Phone: 713-792-5807

11  
12  
13 Fax: 713-563-0059

14  
15 Email: [LMLowenstein@mdanderson.org](mailto:LMLowenstein@mdanderson.org)

16  
17  
18  
19  
20 **Keywords:** Active Surveillance; Cancer; Observational Study; Oncology, Prostatic Neoplasms;

21  
22  
23 Qualitative Evaluation; Treatment Adherence and Compliance

## ABSTRACT

**Objective:** Little is known about clinicians' decision-making about decreasing active surveillance (AS) testing/converting patients to watchful waiting (WW), nor are there any guidelines. The objective of this study was to identify factors that clinicians consider when decreasing AS testing/converting to WW for men with prostate cancer.

**Design:** Exploratory qualitative study.

**Setting:** All participants practiced in various institutions in the U.S.

**Participants:** Eligible clinicians had to provide clinical care for patients with prostate cancer in the U.S. and speak English. Clinicians could be either urologists or radiation oncologists. Of the 24 clinicians, 83% were urologists representing 11 states, 92% were male, and 62% were White.

**Methods:** This qualitative study used data from semi-structured interviews. Purposive sampling was used to ensure geographic variation in the U.S. Data collection continued until thematic saturation was achieved. Framework analysis guided coding and identification of themes. Two researchers coded all transcripts independently, met to discuss, and reached consensus.

**Results:** Interviews with clinicians demonstrated that testing or monitoring for AS or transitioning to WW is happening in practice, whether intentionally or unintentionally. Decisions to decrease AS were personalized and tailored to patients' health status. Life expectancy was the dominant factor that influenced decision, but clinicians were generally hesitant to specify an age when they would decrease AS or transition to WW. Fear that poor adherence could lead to missed progression and concerns about the medical legal issue of not doing enough were cited as barriers to decreasing AS.



1  
2  
3 **Conclusions:** These findings suggest that in certain situations, AS frequency is reduced or  
4 transitioned to WW, yet decisions appear to be inconsistent and there are no significant  
5  
6 barriers. These findings could inform further areas to explore when drafting recommendations  
7  
8 that consider patients' values and preferences when making decisions about decreasing  
9  
10 AS/convertng to WW.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

### **Strengths and Limitations of this study:**

- First study to explore clinician decision making about decreasing AS testing/transitioning to WW for men with prostate cancer.
- Semi-structured interviews with clinicians from different regions of the United States from academic centers and Veterans Affairs hospitals representing 11 states, which unlikely will represent all viewpoints or clinical practices regarding decreasing AS/transitioning to WW for men with prostate cancer.
- Although clinical practice has evolved over the past several years for managing men with prostate cancer on active surveillance, there is no clear consensus nor empirical studies on clinician attitudes on when or how to decrease AS testing/transition to WW.

## BACKGROUND

Many men diagnosed with prostate cancer are diagnosed with localized prostate cancer, which includes those who have low-risk and intermediate risk disease.<sup>1</sup> For many of these men their prostate cancer is unlikely to cause symptoms or affect survival if left untreated.<sup>2,3</sup> In contrast, unnecessary treatment may lead to treatment induced urinary dysfunction, rectal bleeding, and impotence.<sup>4</sup> As a result, overtreatment remains a major concern, with estimates ranging between 6% to 64%.<sup>5</sup> In response, clinical guidelines recommend active surveillance as the preferred management for patients with low-risk disease to minimize overtreatment.<sup>2,6</sup>

The decision to place a man on active surveillance or watchful waiting for prostate cancer is often based upon clinical characteristics of the disease and life expectancy.<sup>3</sup> The National Comprehensive Cancer Network recommends active surveillance as the preferred management strategy for men with at least 10 years of life expectancy if they have low-risk disease; whereas, observation (watchful waiting) is recommended for those with life expectancy <10 years.<sup>6</sup> The American Urological Association, American Society of Radiation Oncology, and the Society of Urologic Oncology recommends active surveillance for men when they have a life expectancy of five years or more.<sup>2</sup> There is some guidance on the frequency and modality of testing, but there is a significant amount of variability in practice.<sup>3,7</sup>

In active surveillance, men are typically monitored closely with prostate-specific antigen (PSA) test every six months, a digital rectal exam at least annually, and repeat prostate biopsies and imaging every one to three years. If the cancer progresses, then curative treatment is delivered.

1  
2  
3 In watchful waiting, men may have fewer tests and rely more on symptom-based monitoring. If  
4  
5 the cancer progresses, then treatment would be started to help control the symptoms but not  
6  
7 cure the cancer.  
8  
9

10  
11  
12 Although there is guidance about when to start active surveillance, discussion or literature on  
13  
14 what clinicians consider or have experienced when decreasing the frequency of testing for  
15  
16 active surveillance and/or transitioning to watchful waiting is largely absent. There is a  
17  
18 commentary<sup>8</sup>, few modelling studie<sup>9,10</sup>, and a narrative review.<sup>11</sup> A consensus statement from  
19  
20 the United Kingdom does state that the decision to convert to watchful waiting should consider  
21  
22 men's preferences, clinical characteristics, comorbidities, functional impairment, and life  
23  
24 expectancy.<sup>12</sup> No currently published study reports on what clinicians think about decreasing  
25  
26 active surveillance and converting to watchful waiting. The purpose of this study was to identify  
27  
28 factors clinicians consider when decreasing surveillance testing frequency or converting to  
29  
30 watchful waiting for prostate cancer.  
31  
32  
33  
34  
35  
36  
37  
38

## 39 **METHODS**

### 40 **Study Design**

41  
42 This study used data from a previously published qualitative study of clinicians that care for  
43  
44 patients with prostate cancer, which reported on physician decision-making regarding general  
45  
46 active surveillance practices such as, protocol selection, comfort with active surveillance,  
47  
48 impact of patient selection for active surveillance.<sup>13</sup> Eligible clinicians had to provide clinical  
49  
50 care for patients with prostate cancer in the United States and speak English. Clinicians could be  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 either urologists or radiation oncologists. All participants provided written informed consent  
4  
5 and completed an intake questionnaire prior to their interview. The University of Texas MD  
6  
7 Anderson Cancer Center Institutional Review Board (PA17-0642) deemed this protocol as  
8  
9 exempt because the study was a secondary analysis of existing data from the parent study. The  
10  
11 parent study was approved by NYU (NYU: i14-02147).  
12  
13  
14  
15  
16  
17

### 18 **Recruitment**

19  
20 Loeb and colleagues used a combination of purposive sampling to select urologists from both  
21  
22 the American Urological Association and the American Society of Clinical Oncology  
23  
24 memberships and snowball sampling.<sup>13</sup> Purposive sampling is a non-probability sampling  
25  
26 strategy to obtain information for a pre-specified population and ensured that each clinician  
27  
28 provided care for men with localized prostate cancer on active surveillance and were from  
29  
30 geographically diverse settings across the United States. Eligible clinicians who were informed  
31  
32 about the study were allowed to nominate other colleagues as potential participants as long as  
33  
34 they also met eligibility criteria. Participants were contacted by email and were given the choice  
35  
36 to have their interview either in person, or over the phone.  
37  
38  
39  
40  
41  
42  
43  
44

### 45 **Data Collection and Management**

46  
47 All interviews were conducted from July to December of 2015 either over the phone or in  
48  
49 person by a female urologist or a female research assistant. Data collection procedures were  
50  
51 described previously.<sup>13</sup> In brief, that study initially conducted 17 interviews, and then  
52  
53 conducted seven more interviews to reach thematic saturation. Thematic saturation is  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 commonly used to determine when enough interviews have been conducted and when no new  
4  
5 insights are identified.<sup>14</sup> Interviews were conducted with the study participants only and lasted  
6  
7  
8 between 22 to 51 minutes. Atlas.ti was used to facilitate data management and analysis.  
9

### 10 11 12 13 **Interview**

14  
15 The interviewers used a semi-structured interview guide that was developed from a literature  
16  
17 review and previous active surveillance research.<sup>15 15-18</sup> The guide was pilot tested with two  
18  
19 clinicians and was edited for improved clarity. The guide consisted of fifteen questions,  
20  
21 including “What are your triggers to stop active surveillance and convert to watchful waiting?”  
22  
23 and “What are your main concerns about active surveillance?” All interviews were audio  
24  
25 recorded and anonymously transcribed by a third-party service.  
26  
27  
28  
29

### 30 31 **Analysis**

32  
33 For this study, framework analysis guided our analytical approach.<sup>19,20</sup> Two researchers  
34  
35 independently reviewed each full transcript and coded any discussion relevant to de-escalating  
36  
37 AS or transitioning to WW. As coding progressed, researchers met and discussed how to  
38  
39 organize and conceptualize the coded text. We charted the coded text into matrices to facilitate  
40  
41 identification of themes. We determined that data saturation was reached when the coded  
42  
43 interviews did not generate additional codes or themes or further our understanding.  
44  
45  
46  
47  
48  
49

### 50 51 **Patient and Public Involvement**

52  
53 No patient involvement.  
54  
55  
56  
57  
58  
59  
60

## RESULTS

### Sample characteristics

A total of 24 clinicians agreed to participate out of the 48 invited. The characteristics of the participants were published previously.<sup>13</sup> Majority of the clinicians were urologists (n=20), male (n=22), and White (n=15) and represented 11 states.

### Overview of qualitative findings

These interviews suggested that some clinicians are reducing the frequency of surveillance testing and transitioning patients to watchful waiting, whether intentionally or unintentionally. Life expectancy considering age and existing comorbidities was the dominant factor influencing these decisions. However, there were some barriers to decreasing test frequency and transitioning to watchful waiting. One barrier is the concern of poor adherence leading to missed disease progression. They also discussed the fear of being potentially sued.

#### *Patient Preferences May Be Leading to Reduced Testing and Converting to Watchful Waiting*

Patients and/or clinicians are reducing the frequency of surveillance testing, whether unintentionally or intentionally. The surveillance testing frequency may be spread out due to patients missing or cancelling appointments. Reasons could include the general discomfort with the biopsy procedure and/or issues with transportation. They also noted that the appointments take time, which interferes with their work.

1  
2  
3 *“Because not just with these patients but every patient has to come to the office every three*  
4 *months, take time off work or you know, wait in the office. I think that really bugs them.”*  
5  
6  
7

8 Clinician 19  
9

10  
11  
12  
13 One clinician mentioned how there isn't really a trigger to switch to watchful waiting, unless  
14 patients stops showing up.  
15  
16

17  
18  
19  
20 *“Yes if you mean by watchful waiting we don't see the people or the individuals anymore or*  
21 *perform any other tests on them then I would say we don't ever convert someone to*  
22 *watchful waiting unless they can't make it back for a visit.”* Clinician 14  
23  
24  
25  
26  
27

28  
29  
30 Clinicians discussed situations where the patients have wanted to switch to watchful waiting  
31 because they have not progressed for many years.  
32  
33

34  
35  
36  
37 *“[...] he actually went through like five years of yearly consecutive biopsies where his PSA*  
38 *didn't change much, his DRE is the same. The pathology was nothing or one or two core*  
39 *right. And, you know, alternating, you know, nothing or a little something. And after year*  
40 *five he was like I'm done, you know, no more we're done. I'm like you know what if I were*  
41 *you I would do the same thing.”* Clinician 07  
42  
43  
44  
45  
46  
47  
48  
49

50  
51  
52 *The role of life expectancy, age, and comorbidities*  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Life expectancy, considering age and comorbidities, was the primary factor that influenced  
4  
5 decisions to reduce surveillance testing and/or transition to watchful waiting. The decision to  
6  
7 space out testing required clinicians to balance a patient's risk of dying from prostate cancer  
8  
9 compared to their other comorbidities, and how the patient values its impact on quality of life  
10  
11 and potential for benefit.  
12  
13  
14

15  
16  
17  
18 *"Well, whenever I see a patient, we're always thinking about based on what we know about*  
19  
20 *this patient now, what's their risk of dying of prostate cancer, and then what's their risk of*  
21  
22 *dying of other disease? And finally, how do they value their quality of life?"* Clinician 18  
23  
24  
25

26  
27  
28 It was clear that clinicians tailor their decisions about transitioning to watchful waiting based on  
29  
30 patients' health status.  
31  
32  
33

34  
35 *"I mean, there's two different scenarios. One scenario is you've watched someone for a*  
36  
37 *while; maybe you've gotten biopsies on them. Their PSA has remained stable, and now*  
38  
39 *you know, instead of being in the early seventies, now they're in their late seventies or*  
40  
41 *early eighties, and so I think it's reasonable to convert that person to an observation...*  
42  
43  
44 *On the other hand, I think that there are some patients that you can look at very quickly*  
45  
46 *and see this is a patient who's not going to benefit from repeat biopsy or close*  
47  
48 *monitoring because they have too many other medical issues that they're dealing with."*  
49  
50  
51  
52 Clinician 03  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 In general, clinicians were reticent to specify an exact age where they would consistently  
4 transition to watchful waiting. One clinician noted the need for a guideline to guide this  
5  
6 transition to watchful waiting. One clinician noted the need for a guideline to guide this  
7  
8 decision.  
9

10  
11  
12  
13 *“But I would think like after the age of 80, you know, we could probably just stop*  
14 *because you know, you and I know that you know, most men already are going to have*  
15 *prostate cancer. Most men over 70 will have some cancer cells in them. But I would need*  
16 *some kind of guideline or something somewhere.”* Clinician 19  
17  
18  
19  
20  
21  
22  
23  
24

25 However, one clinician felt that 75 years should be the cut-off and will only keep patients on AS  
26 if they insist.  
27  
28  
29  
30  
31

32 *“I would say if someone is on it for 6 years, has gone through our protocol and now*  
33 *they’re over 75 years of age then I’ll move to, I’ll go to watchful waiting... I tell them if*  
34 *you came to me with a normal PSA and a normal rectal exam since age 75 I would stop*  
35 *following you at age 75. Sometimes I’ll go to 80 if they’re really healthy and they’re*  
36 *insisting on it but most patients I try to encourage them to say listen we’ve made it to 75*  
37 *without a problem it’s reasonable to just not check it.”* Clinician 09  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 *Barriers to decrease testing and transitioning to watchful waiting*

51  
52 Concerns about poor adherence leading to missed disease progression. One barrier to

53 decreasing test frequency or transitioning to watchful waiting was clinicians’ concern about  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 poor adherence, resulting in missing disease progression. One clinician had a patient who did  
4  
5 not adhere to the active surveillance schedule and came back and had progressed.  
6  
7  
8  
9

10 *“Cause if you’ve got a patient that should come back in six months and they kind of fall off*  
11 *the radar, then there’s a chance that there are patients out there -- by the way, this*  
12 *happened a couple times where patients come back a year and a half later and they’ve had*  
13 *progression... that if patients aren’t compliant, then active surveillance doesn’t work.”*  
14  
15  
16  
17  
18  
19

20 Clinician 06  
21  
22  
23  
24

25 The experience of having missed a progression due to poor adherence could perpetuate  
26  
27 clinicians fear of missed progression and deter them from wanting to de-escalate active  
28  
29 surveillance or transition to watchful waiting because they do not know which patients will  
30  
31 have cancer progression.  
32  
33  
34  
35  
36

37 Fear of litigation/retribution. Clinicians expressed that fear of legal action is in the back of their  
38  
39 mind, but acknowledged that it is rare that they are sued.  
40  
41  
42  
43  
44

45 *“The third barrier is worry over legal stuff although I’ve never heard of someone being sued*  
46 *because of surveillance or not but I think that’s in the back of people’s minds. When I talk to*  
47 *private practice guys they say that”.* Clinician 12  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The fear of litigation is further amplified by the misalignment of active surveillance and the  
4 natural context of the field and purpose of their work.  
5  
6  
7  
8  
9

10 *“Well there is misalignment of how should I say let’s say perverse incentives for managing*  
11 *people with low grade disease. In other words, physicians get reimbursed for doing*  
12 *something not for doing nothing.”* Clinician 14  
13  
14  
15  
16  
17  
18  
19

## 20 **DISCUSSION**

21  
22 Our qualitative analysis suggest that surveillance testing for prostate cancer is being decreased  
23 and/or transitioned to watchful waiting in clinical practice. Intentional decisions to decrease  
24 surveillance testing/transition to watchful waiting may consider patients’ age, health, and life  
25 expectancy. These decisions may also take into consideration patients’ values and preferences.  
26 Unintentional decisions to decrease surveillance testing/transition to watchful waiting may be  
27 due to missed or cancelled appointments. These missed appointments may be an indicator that  
28 patients are prioritizing their quality of life or ability to work over the management of their  
29 prostate cancer.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 This study suggests that the issues of age, health, and life expectancy may also play a role in  
46 decisions to decrease surveillance testing or transitioning to watchful waiting, similar to the  
47 decisions to start active surveillance.<sup>2122</sup> In contrast, a study where clinicians were presented  
48 with scenarios and rank ordered factors that influenced their decision making about starting  
49 active surveillance, found that clinicians used 10-year survival probability, stage, and PSA.<sup>23</sup>  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 A modeling study demonstrated that generally active surveillance had greater quality adjusted  
7  
8 life years than watchful waiting, except among patients diagnosed older than 65 years.<sup>24</sup>  
9

10 Another study found that for men older than 65 years, one biopsy round resulted in a loss of  
11  
12 one quality adjusted life year, likely due to other quality of life outcomes and potential biopsy-  
13  
14 related complications.<sup>9</sup> The University of Toronto stops serial biopsies once a man is 80 years  
15  
16 old and has a life expectancy of less-than five years.<sup>25</sup> However, the consensus statement from  
17  
18 the United Kingdom does state that age as well as other factors need to be considered,  
19  
20 including frailty.<sup>12</sup>  
21  
22  
23  
24  
25  
26  
27

28 As time on active surveillance increases, clinicians' and patients' comfort with active  
29  
30 surveillance and acceptance of the low probability of progression may support them in making  
31  
32 the decision to decrease the frequency of surveillance testing/transition to watchful waiting.  
33  
34

35 This finding is consistent with the literature around men who select active surveillance. Patients  
36  
37 and their families who may be more anxious are less likely to choose active surveillance initially  
38  
39 or stop active surveillance for immediate treatment.<sup>21,26</sup> One qualitative study found that men  
40  
41 on active surveillance understood their disease was low-risk and were confident there would be  
42  
43 time for curative treatment if they progressed. These men also had to convince family members  
44  
45 that they were not crazy for having a cancer and not treating it immediately.<sup>27</sup> In a study that  
46  
47 followed men on active surveillance for three years found that over time, men adopted coping  
48  
49 mechanisms and became less anxious about their prostate cancer.<sup>28</sup>  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The issue of adherence may be associated with the fear of missing the window of curability,  
4 which then in turn may serve as a barrier to decreasing surveillance testing or transitioning to  
5 watchful waiting. Clinicians noted that active surveillance only works if patients show up for the  
6 appointments. However, they recognized that there are practical barriers (e.g., transportation  
7 issues and time off from work) that may contribute to nonadherence to the active surveillance  
8 protocol. In a large cohort of men with grade group 1 prostate cancer, about 24% were lost to  
9 follow-up among men who were not reclassified.<sup>29</sup> However, the increased use of telemedicine  
10 due to the COVID-19 pandemic may help with some of the practical barriers in the future. It  
11 may also help to explore the goals of care at the start of active surveillance and during active  
12 surveillance, so that the clinicians can be aware of what is important to the patient. Another  
13 would be to set the expectation that surveillance testing may decrease over time and that they  
14 may transition to watchful waiting in the future. The MUSIC improvement program is taking this  
15 approach to their active surveillance patients.<sup>30</sup>

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37 Finally, the fear of litigation may be a barrier to decreasing testing for disease progression and  
38 transitioning to watchful waiting. The fear of litigation is likely related to the fear of missing a  
39 cancer that will become metastatic and its downstream consequences, such as patients and  
40 family members being upset and wanting to sue or submit a complaint. The qualitative study by  
41 Loeb and colleagues found that there are medico-legal considerations when starting active  
42 surveillance because the clinicians felt the need to protect themselves.<sup>13</sup>

1  
2  
3 Although this study provides new information regarding what clinicians consider when making  
4 the decision to decrease the frequency of surveillance monitoring or to transition to watchful  
5 waiting, limitations need to be considered when interpreting the results. The interviews  
6  
7 focused on a variety of issues about active surveillance, such as testing frequency and modality  
8  
9 and decreasing surveillance testing frequency or converting to watchful waiting were only one  
10  
11 area of focus. The sample consisted of clinicians at academic and Veterans Affairs hospitals  
12  
13 representing 11 states. Their perspectives and the patients they treat may not represent the  
14  
15 wider group of clinicians who see and treat men with prostate cancer, such as general  
16  
17 urologists and primary care providers outside of the institutions in this study. Additionally,  
18  
19 clinicians who practice outside the United States may have different experiences because of the  
20  
21 differences in the healthcare system. Some of the interviews were conducted by a female  
22  
23 urologist who is well known among the medical community, which may have introduced  
24  
25 response bias. However, this interviewer used open-ended and non-judgmental questioning to  
26  
27 facilitate an open-dialogue. The interviewers did not participate in the analysis process for this  
28  
29 study, limiting the ability to incorporate the insights of the interviewers in the analysis process.  
30  
31 The results and interpretation of this analysis was shared and discussed with the primary study  
32  
33 lead and interviewer.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 Since the time of the interviews, it is possible that clinical practices regarding de-escalation of  
48  
49 active surveillance and transitioning to watchful waiting have changed. However, the AUA  
50  
51 guidelines on the management of localized prostate cancer does not address the issue of when  
52  
53 or how to de-escalate active surveillance and transition to watchful waiting.<sup>2</sup> The authors aware  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 of one formal group that has a staged approach to active surveillance, the Michigan Urological  
4  
5 Surgery Initiative.<sup>30</sup>  
6  
7  
8  
9

10 These findings suggested that decreasing surveillance testing frequency or transitioning to  
11  
12 watchful waiting may be happening in certain situations. More research is needed to explore all  
13  
14 the scenarios when clinicians and patients may be amenable to decreasing active surveillance  
15  
16 testing or transitioning to watchful waiting and communication strategies to facilitate this  
17  
18 difficult conversation. These decisions are preference-sensitive and patients' values and  
19  
20 priorities in addition to their health status needs to be considered. Interventions to support  
21  
22 shared decision making, such as patient facing decision aids and encounter based decision aids,  
23  
24 may be helpful to identify patients' values and goals of care in making the decision to transition  
25  
26 to watchful waiting. Clinicians and men need guidance to make thoughtful decisions to  
27  
28 decrease surveillance testing or transition to watchful waiting. These guidelines could also  
29  
30 emphasize the need to consider men's preferences in addition to clinical characteristics and  
31  
32 encourage shared decision making.  
33  
34  
35  
36  
37  
38  
39  
40  
41

#### 42 **Contributorship statement**

43 Study conception and design: LML; drafting of the study protocol: LML; obtaining of research  
44  
45 funding: LML and SL; acquisition of data: SL. performing of qualitative analysis: LML and NJC  
46  
47 drafting, editing and preparing of the final version of the manuscript: LML, NJC, and SL; Critical  
48  
49 feedback and additional edits: NJC, RJV, KEH, and SL. All authors approved the final manuscript.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Funding

Financial Support: This work was supported by a grant from The University of Texas MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment (Shared Decision Making Collaborative) and a grant from NIH/NCI under award number P30CA016672 (Clinical Protocol and Data Management, and Shared Decision Making Core). Dr. Lowenstein was supported by the American Cancer Society under Award Number MRS-18-225-01-CPPB. Additionally, this work was supported through the Prostate Cancer Foundation, Feldstein Medical Foundation, Edward Blank and Sharon Cosloy-Blank Family Foundation, the Gertrude and Louis Feil Family, the New York Department of Health (DOH01-C30697GG-3450000), The Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center (P30CA016087), and the NIH (Award Number K07CA178258) to Dr. Loeb. The content is solely the responsibility of the authors and does not represent the official views of the NIH.

## Data Sharing Statement

Research data are not shared.

## Ethics Statements

### Patient consent for publication

Not required

### Ethics approval

The University of Texas MD Anderson Cancer Center Institutional Review Board (PA17-0642) deemed this protocol as exempt because the study was a secondary analysis of existing data from the parent study. The parent study was approved by NYU (NYU: i14-02147).

### Competing Interests

The authors have no competing interests to report.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Siegel DA, O'Neil MA, Richards TB, Dowling NF, Weir HK. *Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001-2017*. 2020.
2. Sanda MG, Chen RC, Crispino T, et al. *Clinically localized prostate cancer: AUA/ASTRO/SUO guideline*. 2017.
3. Bruinsma SM, Bangma CH, Carroll PR, et al. Active surveillance for prostate cancer: a narrative review of clinical guidelines. *Nat Rev Urol*. 2016;13(3):151-167.
4. Hoffman RM, Lobo T, Van Den Eeden SK, et al. Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer. *Med Decis Making*. 2019;39(8):962-974.
5. Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. *Eur Urol*. 2014;65(6):1046-1055.
6. Carroll PR, Parsons JK, Andriole G, et al. NCCN guidelines insights: prostate cancer early detection, version 2.2016. *J Natl Compr Canc Netw*. 2016;14(5):509-519.
7. Lowenstein LM, Basourakos SP, Williams MD, et al. Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned. *Nat Rev Clin Oncol*. 2019;16(3):168-184.
8. Loeb S. Overactive Surveillance: Is "Conservative"; Management for Low-risk Prostate Cancer Too Aggressive? *European Urology*. 2019;76(4):467-468.
9. de Carvalho TM, Heijnsdijk EAM, de Koning HJ. When should active surveillance for prostate cancer stop if no progression is detected? *The Prostate*. 2017;77(9):962-969.

10. Van Hemelrijck M, Garmo H, Lindhagen L, Bratt O, Stattin P, Adolfsson J. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer. *European Urology*. 2017;72(4):534-541.
11. Rajwa P, Sprenkle PC, Leapman MS. When and How Should Active Surveillance for Prostate Cancer be De-Escalated? *European Urology Focus*. 2020.
12. Merriel SWD, Hetherington L, Seggie A, et al. Best practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement. *BJU International*. 2019;124(1):47-54.
13. Loeb S, Curnyn C, Fagerlin A, et al. Qualitative study on decision-making by prostate cancer physicians during active surveillance. *BJU International*. 2017;120(1):32-39.
14. Sandelowski M. Sample size in qualitative research. *Research in Nursing & Health*. 1995;18(2):179-183.
15. Davison BJ, Goldenberg SL. Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer. *BJU Int*. 2011;108(11):1787-1793.
16. O'Callaghan C, Dryden T, Hyatt A, et al. 'What is this active surveillance thing?' Men's and partners' reactions to treatment decision making for prostate cancer when active surveillance is the recommended treatment option. *Psycho-Oncology*. 2014;23(12):1391-1398.
17. Kazer MW, Bailey Jr DE, Colberg J, Kelly WK, Carroll P. The needs for men undergoing active surveillance (AS) for prostate cancer: results of a focus group study. *Journal of Clinical Nursing*. 2011;20(3-4):581-586.

18. Mishra MV, Bennett M, Vincent A, et al. Identifying Barriers to Patient Acceptance of Active Surveillance: Content Analysis of Online Patient Communications. *PLOS ONE*. 2013;8(9):e68563.
19. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: Bryman A, Burgess RG, eds. *Analyzing Qualitative Data*. London: Routledge; 1994:172-194.
20. Ritchie J, Spencer L, O'Connor W. Carrying out qualitative analysis. In: Ritchie J, Lewis J, eds. *Qualitative Research Practice: A Guide for Social Science Students and Researchers*. London: Sage; 2003:219-262.
21. Pang K, Fitch M, Ouellet V, et al. Describing perspectives of health care professionals on active surveillance for the management of prostate cancer. *BMC Health Serv Res*. 2018;18(1):430-430.
22. Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate Cancer, Version 1.2016. *J Natl Compr Canc Netw*. 2016;14(1):19-30.
23. Clarke MG, Wilson JRM, Kennedy KP, MacDonagh RP. Clinical Judgment Analysis of the Parameters Used by Consultant Urologists in the Management of Prostate Cancer. *Journal of Urology*. 2007;178(1):98-102.
24. Loeb S, Zhou Q, Siebert U, et al. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. *European Urology*. 2017.
25. Garisto JD, Klotz L. Active Surveillance for Prostate Cancer: How to Do It Right. *Oncology (Williston Park)*. 2017;31(5):333-340, 345.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
26. Berger ZD, Yeh JC, Carter HB, Pollack CE. Characteristics and experiences of patients with localized prostate cancer who left an active surveillance program. *Patient*. 2014;7(4):427-436.
27. Volk RJ, McFall SL, Cantor SB, et al. 'It's not like you just had a heart attack': decision-making about active surveillance by men with localized prostate cancer. *Psychooncology*. 2014;23(4):467-472.
28. Dordoni P, Badenchini F, Alvisi MF, et al. How do prostate cancer patients navigate the active surveillance journey? A 3-year longitudinal study. *Supportive Care in Cancer*. 2021;29(2):645-651.
29. Tosoian JJ, Mamawala M, Epstein JI, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. *European Urology*. 2020.
30. Michigan Urological Surgery Initiative. Active Surveillance Roadmap for Management of Men With Favorable-Risk Prostate Cancer. <https://musicurology.com/active-surveillance/>. Accessed June 1, 2021.

## Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist

No	Item	Guide questions/description	Page
<b>Domain 1: Research team and reflexivity</b>			
Personal Characteristics			
1.	Interviewer/facilitator	Which author/s conducted the interview or focus group?	16
2.	Credentials	What were the researcher's credentials? <i>E.g. PhD, MD</i>	1
3.	Occupation	What was their occupation at the time of the study?	1
4.	Gender	Was the researcher male or female?	16
5.	Experience and training	What experience or training did the researcher have?	1
Relationship with participants			
6.	Relationship established	Was a relationship established prior to study commencement?	16
7.	Participant knowledge of the interviewer	What did the participants know about the researcher? <i>e.g. personal goals, reasons for doing the research</i>	16
8.	Interviewer characteristics	What characteristics were reported about the interviewer/facilitator? <i>e.g. Bias, assumptions, reasons and interests in the research topic</i>	16
<b>Domain 2: study design</b>			
Theoretical framework			
9.	Methodological orientation and Theory	What methodological orientation was stated to underpin the study? <i>e.g. grounded theory, discourse analysis, ethnography, phenomenology, content analysis</i>	7

No	Item	Guide questions/description	Page
Participant selection			
10.	Sampling	How were participants selected? <i>e.g. purposive, convenience, consecutive, snowball</i>	8
11.	Method of approach	How were participants approached? <i>e.g. face-to-face, telephone, mail, email</i>	8
12.	Sample size	How many participants were in the study?	8
13.	Non-participation	How many people refused to participate or dropped out? Reasons?	9
Setting			
14.	Setting of data collection	Where was the data collected? <i>e.g. home, clinic, workplace</i>	8
15.	Presence of non-participants	Was anyone else present besides the participants and researchers?	8
16.	Description of sample	What are the important characteristics of the sample? <i>e.g. demographic data, date</i>	7
Data collection			
17.	Interview guide	Were questions, prompts, guides provided by the authors? Was it pilot tested?	8
18.	Repeat interviews	Were repeat interviews carried out? If yes, how many?	8
19.	Audio/visual recording	Did the research use audio or visual recording to collect the data?	8
20.	Field notes	Were field notes made during and/or after the interview or focus group?	NR
21.	Duration	What was the duration of the interviews or focus group?	8



No	Item	Guide questions/description	Page
22.	Data saturation	Was data saturation discussed?	8
23.	Transcripts returned	Were transcripts returned to participants for comment and/or correction?	NR
<b>Domain 3: analysis and findings</b>			
Data analysis			
24.	Number of data coders	How many data coders coded the data?	9
25.	Description of the coding tree	Did authors provide a description of the coding tree?	NR
26.	Derivation of themes	Were themes identified in advance or derived from the data?	9
27.	Software	What software, if applicable, was used to manage the data?	8
28.	Participant checking	Did participants provide feedback on the findings?	NR
Reporting			
29.	Quotations presented	Were participant quotations presented to illustrate the themes / findings? Was each quotation identified? e.g. <i>participant number</i>	10
30.	Data and findings consistent	Was there consistency between the data presented and the findings?	10
31.	Clarity of major themes	Were major themes clearly presented in the findings?	9
32.	Clarity of minor themes	Is there a description of diverse cases or discussion of minor themes?	10

# BMJ Open

## Factors that Influence Clinicians' Decisions to Decrease Active Surveillance Monitoring Frequency or Transition to Watchful Waiting for Localized Prostate Cancer: A Qualitative Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048347.R2
Article Type:	Original research
Date Submitted by the Author:	19-Oct-2021
Complete List of Authors:	Lowenstein, Lisa; The University of Texas MD Anderson Cancer Center Division of Cancer Prevention and Population Sciences, Health Services Research Choi, Noah; The University of Texas MD Anderson Cancer Center Division of Cancer Prevention and Population Sciences, Health Services Research Hoffman, Karen; MD Anderson Division of Radiation Oncology, Radiation Oncology Volk, Robert; The University of Texas MD Anderson Cancer Center Division of Cancer Prevention and Population Sciences, Health Services Research Loeb, Stacy; New York University, Urology, Population Health
<b>Primary Subject Heading</b>:	Health services research
Secondary Subject Heading:	Qualitative research, Oncology
Keywords:	Urological tumours < ONCOLOGY, GENITOURINARY MEDICINE, GERIATRIC MEDICINE, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, QUALITATIVE RESEARCH

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Factors that Influence Clinicians' Decisions to Decrease Active Surveillance Monitoring**  
4  
5  
6 **Frequency or Transition to Watchful Waiting for Localized Prostate Cancer: A Qualitative**  
7  
8 **Study**  
9

10  
11  
12  
13 **Short Title: Decisions about Transitioning to Watchful Waiting for Prostate Cancer**  
14

15  
16  
17  
18 Lisa M. Lowenstein, PhD, MPH<sup>a</sup>  
19

20 Noah J. Choi<sup>a</sup>  
21

22 Karen E. Hoffman, MD, MPH<sup>b</sup>  
23

24 Robert J. Volk, PhD<sup>a</sup>  
25

26 Stacy Loeb, MD, MSc, PhD (Hon)<sup>c, d, e</sup>  
27

28  
29  
30  
31  
32 <sup>a</sup> Department of Health Services Research, The University of Texas MD Anderson Cancer Center,  
33  
34 1400 Pressler Street, Unit 1444, Houston, TX 77230, USA.  
35

36  
37 <sup>b</sup> Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center  
38

39  
40 <sup>c</sup> Department of Urology, New York University, New York City, USA  
41

42 <sup>d</sup> Department of Population Health, New York University, New York City, USA  
43

44  
45 <sup>e</sup> Manhattan Veterans Affairs Medical Center, New York City, USA  
46

47  
48  
49 **Corresponding Author:**  
50

51  
52 Lisa M. Lowenstein, PhD, MPH  
53

54 Department of Health Services Research  
55  
56  
57  
58  
59  
60

1  
2  
3 The University of Texas MD Anderson Cancer Center

4  
5  
6 1400 Pressler Street, Unit 1444

7  
8 Houston, TX 77230

9  
10 Phone: 713-792-5807

11  
12  
13 Fax: 713-563-0059

14  
15 Email: [LMLowenstein@mdanderson.org](mailto:LMLowenstein@mdanderson.org)

16  
17  
18  
19  
20 **Keywords:** Active Surveillance; Cancer; Observational Study; Oncology, Prostatic Neoplasms;

21  
22  
23 Qualitative Evaluation; Treatment Adherence and Compliance

## ABSTRACT

**Objective:** Little is known about clinicians' decision-making about decreasing active surveillance (AS) testing/converting patients to watchful waiting (WW), nor are there any guidelines. The objective of this study was to identify factors that clinicians consider when decreasing AS testing/converting to WW for men with prostate cancer.

**Design:** Exploratory qualitative study.

**Setting:** All participants practiced in various institutions in the U.S.

**Participants:** Eligible clinicians had to provide clinical care for patients with prostate cancer in the U.S. and speak English. Clinicians could be either urologists or radiation oncologists. Of the 24 clinicians, 83% were urologists representing 11 states, 92% were male, and 62% were White.

**Methods:** This qualitative study used data from semi-structured interviews. Purposive sampling was used to ensure geographic variation in the U.S. Data collection continued until thematic saturation was achieved. Framework analysis guided coding and identification of themes. Two researchers coded all transcripts independently, met to discuss, and reached consensus.

**Results:** Interviews with clinicians demonstrated that testing or monitoring for AS or transitioning to WW is happening in practice, whether intentionally or unintentionally. Decisions to decrease AS were personalized and tailored to patients' health status. Life expectancy was the dominant factor that influenced decision, but clinicians were generally hesitant to specify an age when they would decrease AS or transition to WW. Fear that poor adherence could lead to missed progression and concerns about the medico-legal issue of not doing enough were cited as barriers to decreasing AS.

1  
2  
3 **Conclusions:** These findings suggest that in certain situations, AS frequency is reduced or  
4 transitioned to WW, yet decisions appear to be inconsistent and there are no significant  
5  
6 barriers. These findings could inform further areas to explore when drafting recommendations  
7  
8 that consider patients' values and preferences when making decisions about decreasing  
9  
10 AS/convertng to WW.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Strengths and Limitations of this study:**

- First study to explore clinician decision making about decreasing AS testing/transitioning to WW for men with prostate cancer.
- Data from these semi-structured interviews with clinicians from different regions of the United States from academic centers and Veterans Affairs hospitals representing 11 states, may not represent all viewpoints or clinical practices regarding decreasing AS/transitioning to WW for men with prostate cancer.
- Although clinical practice has evolved over the past several years for managing men with prostate cancer on active surveillance, there is no clear consensus nor empirical studies on clinician attitudes on when or how to decrease AS testing/transition to WW.



## BACKGROUND

Many men diagnosed with prostate cancer are diagnosed with localized prostate cancer, which includes those who have low-risk and intermediate risk disease.<sup>1</sup> For many of these men their prostate cancer is unlikely to cause symptoms or affect survival if left untreated.<sup>2,3</sup> In contrast, unnecessary treatment may lead to treatment induced urinary problems, rectal bleeding, and sexual dysfunction.<sup>4</sup> As a result, overtreatment remains a major concern, with estimates ranging between 6% to 64%.<sup>5</sup> In response, clinical guidelines recommend active surveillance as the preferred management for patients with low-risk disease to minimize overtreatment.<sup>2,6</sup>

The decision about active surveillance or watchful waiting for prostate cancer includes consideration of clinical characteristics of the disease and life expectancy.<sup>3</sup> The National Comprehensive Cancer Network recommends active surveillance as for men with at least 10 years of life expectancy if they have low-risk disease; whereas, observation (watchful waiting) is recommended for those with life expectancy <10 years.<sup>6</sup> The American Urological Association, American Society of Radiation Oncology, and the Society of Urologic Oncology recommends active surveillance for men when they have a life expectancy of five years or more.<sup>2</sup> There is some guidance on the frequency and modality of testing, but there is a significant amount of variability in practice.<sup>3,7</sup>

In active surveillance, men are typically monitored closely with prostate-specific antigen (PSA) test every six months, a digital rectal exam at least annually, and repeat prostate biopsies and imaging every one to three years. If the cancer progresses, then curative treatment is delivered.

1  
2  
3 In watchful waiting, men may have fewer tests and rely more on symptom-based monitoring. If  
4  
5 the cancer progresses, then treatment would be started to help control the symptoms but not  
6  
7 cure the cancer.  
8  
9

10  
11  
12 Although there is guidance about when to start active surveillance, discussion or literature on  
13  
14 what clinicians consider or have experienced when decreasing the frequency of testing for  
15  
16 active surveillance and/or transitioning to watchful waiting is largely absent. There is a  
17  
18 commentary,<sup>8</sup> few modelling studies,<sup>9,10</sup> and a narrative review.<sup>11</sup> These articles indicate that  
19  
20 the decision to de-escalate active surveillance and/or convert to watchful waiting is complex  
21  
22 and needs to consider age, comorbidities, and patient preferences. A consensus statement  
23  
24 from the United Kingdom does state that the decision to convert to watchful waiting should  
25  
26 consider men's preferences, clinical characteristics, comorbidities, functional impairment, and  
27  
28 life expectancy.<sup>12</sup> No currently published study reports on what clinicians think about  
29  
30 decreasing active surveillance and/or converting to watchful waiting. The purpose of this study  
31  
32 was to identify factors clinicians consider when decreasing surveillance testing frequency or  
33  
34 converting to watchful waiting for prostate cancer.  
35  
36  
37  
38  
39  
40  
41  
42  
43

## 44 **METHODS**

### 45 **Study Design**

46  
47  
48 This study used data from a previously published qualitative study of clinicians that care for  
49  
50 patients with prostate cancer, which reported on physician decision-making regarding general  
51  
52 active surveillance practices such as, protocol selection, comfort with active surveillance,  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 impact of patient selection for active surveillance.<sup>13</sup> Eligible clinicians had to provide clinical  
4 care for patients with prostate cancer in the United States and speak English. Clinicians could be  
5 either urologists or radiation oncologists. All participants provided written informed consent  
6 and completed an intake questionnaire prior to their interview. The University of Texas MD  
7 Anderson Cancer Center Institutional Review Board (PA17-0642) deemed this protocol as  
8 exempt because the study was a secondary analysis of existing data from the parent study. The  
9 parent study was approved by NYU (NYU: i14-02147).

## 22 **Recruitment**

23  
24 Loeb and colleagues used a combination of purposive sampling to select urologists from both  
25 the American Urological Association and the American Society of Clinical Oncology  
26 memberships and snowball sampling.<sup>13</sup> Clinicians were enrolled onto the study until data  
27 saturation was reached. Purposive sampling is a non-probability sampling strategy to obtain  
28 information for a pre-specified population and ensured that each clinician provided care for  
29 men with localized prostate cancer on active surveillance and were from geographically diverse  
30 settings across the United States. Eligible clinicians who were informed about the study were  
31 allowed to nominate other colleagues as potential participants as long as they also met  
32 eligibility criteria. Participants were contacted by email and were given the choice to have their  
33 interview either in person, or over the phone.

## 52 **Data Collection and Management**

1  
2  
3 All interviews were conducted from July to December of 2015 either over the phone or in  
4  
5 person by a female urologist or a female research assistant. Data collection procedures were  
6  
7 described previously.<sup>13</sup> In brief, that study initially conducted 17 interviews, and then  
8  
9 conducted seven more interviews to reach thematic saturation. Thematic saturation is  
10  
11 commonly used to determine when enough interviews have been conducted and when no new  
12  
13 insights are identified.<sup>14</sup> Interviews were conducted with the study participants only and lasted  
14  
15 between 22 to 51 minutes. Atlas.ti was used to facilitate data management and analysis.  
16  
17  
18  
19  
20  
21  
22

### 23 **Interview**

24  
25 The interviewers used a semi-structured interview guide that was developed from a literature  
26  
27 review and previous active surveillance research.<sup>15-18</sup> The guide was pilot tested with two  
28  
29 clinicians and was edited for improved clarity. The guide consisted of fifteen questions,  
30  
31 including “What are your triggers to stop active surveillance and convert to watchful waiting?”  
32  
33 and “What are your main concerns about active surveillance?” All interviews were audio  
34  
35 recorded and anonymously transcribed by a third-party service.  
36  
37  
38  
39  
40

### 41 **Analysis**

42  
43 For this study, framework analysis guided our analytical approach.<sup>19,20</sup> Two researchers  
44  
45 independently reviewed each full transcript and coded any discussion relevant to de-escalating  
46  
47 AS or transitioning to WW. Researchers met to discuss their coding and how to organize and  
48  
49 conceptualize the coded text (refine code definitions) until all transcripts were discussed. After  
50  
51 all transcripts were coded, we charted the coded text into matrices, where rows represented  
52  
53 codes and columns represented participants, to facilitate identification of themes. For each  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 participant, we summarized when and how the code was applied and an example quote from  
4  
5 the coded transcript. We determined that data saturation was reached when the coded  
6  
7 interviews did not generate additional codes or themes or further our understanding.  
8  
9

### 10 11 12 13 **Patient and Public Involvement**

14  
15 No patient involvement.  
16  
17

## 18 19 **RESULTS**

### 20 21 **Sample characteristics**

22  
23 A total of 48 invitations were sent with enrollment on a rolling basis. Enrollment was stopped  
24  
25 after 24 clinicians because data saturation was achieved. The characteristics of the participants  
26  
27 were published previously.<sup>13</sup> Majority of the clinicians were urologists (n=20), male (n=22), and  
28  
29 White (n=15) and represented 11 states.  
30  
31  
32  
33

### 34 35 **Overview of qualitative findings**

36  
37 These interviews suggested that some clinicians are reducing the frequency of surveillance  
38  
39 testing and transitioning patients to watchful waiting, whether intentionally (e.g., clinician and  
40  
41 patient discussed de-escalating surveillance testing and/or converting to watchful waiting) or  
42  
43 unintentionally (e.g., patient stopped following up for visits at pre-set intervals, every 6 months  
44  
45 for PSA testing). Life expectancy considering age and existing comorbidities was the dominant  
46  
47 factor influencing these decisions. However, there were some barriers to decreasing test  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 frequency and transitioning to watchful waiting. One barrier is the concern of poor adherence  
4  
5 leading to missed disease progression. They also discussed the fear of being potentially sued.  
6  
7  
8  
9

### 10 *Patient Preferences May Be Leading to Reduced Testing and Converting to Watchful Waiting*

11  
12 Patients and/or clinicians are reducing the frequency of surveillance testing, whether  
13  
14 unintentionally or intentionally. The surveillance testing frequency may be spread out due to  
15  
16 patients missing or cancelling appointments. Reasons could include the general discomfort with  
17  
18 the biopsy procedure and/or issues with transportation. They also noted that the appointments  
19  
20 take time, which interferes with their work.  
21  
22  
23  
24  
25  
26  
27

28 *“Because not just with these patients but every patient has to come to the office every three*  
29  
30 *months, take time off work or you know, wait in the office. I think that really bugs them.”*  
31

32 Clinician 19  
33  
34  
35  
36

37 One clinician mentioned how there isn't really a trigger to switch to watchful waiting, unless  
38  
39 patients stops showing up.  
40  
41  
42  
43

44 *“Yes if you mean by watchful waiting we don't see the people or the individuals anymore or*  
45  
46 *perform any other tests on them then I would say we don't ever convert someone to*  
47  
48 *watchful waiting unless they can't make it back for a visit.”* Clinician 14  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Clinicians discussed situations where the patients have wanted to switch to watchful waiting  
4  
5 because they have not progressed for many years.  
6  
7  
8  
9

10 *"[...] he actually went through like five years of yearly consecutive biopsies where his PSA*  
11 *didn't change much, his DRE is the same. The pathology was nothing or one or two cores.*  
12 *And, you know, alternating, nothing or a little something. And after year five he was like I'm*  
13 *done, no more we're done. I'm like you know what if I were you I would do the same thing."*  
14  
15  
16  
17  
18  
19

20 Clinician 07  
21  
22  
23  
24

### 25 *The role of life expectancy, age, and comorbidities*

26 Life expectancy, considering age and comorbidities, was the primary factor that influenced  
27  
28 decisions to reduce surveillance testing and/or transition to watchful waiting. The decision to  
29  
30 space out testing required clinicians to balance a patient's risk of dying from prostate cancer  
31  
32 compared to their other comorbidities, and how the patient values its impact on quality of life  
33  
34 and potential for benefit.  
35  
36  
37  
38  
39  
40  
41

42 *"Well, whenever I see a patient, we're always thinking about based on what we know about*  
43 *this patient now, what's their risk of dying of prostate cancer, and then what's their risk of*  
44 *dying of other disease? And finally, how do they value their quality of life?"* Clinician 18  
45  
46  
47  
48  
49  
50  
51

52 It was clear that clinicians tailor their decisions about transitioning to watchful waiting based on  
53  
54 patients' health status.  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 *"I mean, there's two different scenarios. One scenario is you've watched someone for a*  
7 *while; maybe you've gotten biopsies on them. Their PSA has remained stable, and now*  
8 *you know, instead of being in the early seventies, now they're in their late seventies or*  
9 *early eighties, and so I think it's reasonable to convert that person to an observation...*  
10 *On the other hand, I think that there are some patients that you can look at very quickly*  
11 *and see this is a patient who's not going to benefit from repeat biopsy or close*  
12 *monitoring because they have too many other medical issues that they're dealing with."*  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23 Clinician 03

24  
25  
26  
27  
28 In general, clinicians were reticent to specify an exact age where they would consistently  
29 transition to watchful waiting. One clinician noted the need for a guideline to guide this  
30 decision.  
31  
32  
33

34  
35  
36  
37 *"But I would think like after the age of 80, you know, we could probably just stop*  
38 *because you know, you and I know that you know, most men already are going to have*  
39 *prostate cancer. Most men over 70 will have some cancer cells in them. But I would need*  
40 *some kind of guideline or something somewhere."* Clinician 19  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 However, one clinician felt that 75 years should be the cut-off and will only keep patients on AS  
51 if they insist.  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 *"I would say if someone is on it for 6 years, has gone through our protocol and now*  
4 *they're over 75 years of age then I'll move to, I'll go to watchful waiting... I tell them if*  
5 *you came to me with a normal PSA and a normal rectal exam since age 75 I would stop*  
6 *following you at age 75. Sometimes I'll go to 80 if they're really healthy and they're*  
7 *insisting on it but most patients I try to encourage them to say listen we've made it to 75*  
8 *without a problem it's reasonable to just not check it."* Clinician 09  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

### 20 *Barriers to decrease testing and transitioning to watchful waiting*

21 Concerns about poor adherence leading to missed disease progression. One barrier to  
22  
23 decreasing test frequency or transitioning to watchful waiting was clinicians' concern about  
24  
25 poor adherence, resulting in missing disease progression. One clinician had a patient who did  
26  
27 not adhere to the active surveillance schedule and came back and had progressed.  
28  
29  
30  
31  
32  
33  
34

35 *"Cause if you've got a patient that should come back in six months and they kind of fall off*  
36 *the radar, then there's a chance that there are patients out there -- by the way, this*  
37 *happened a couple times where patients come back a year and a half later and they've had*  
38 *progression... that if patients aren't compliant, then active surveillance doesn't work."*  
39  
40  
41  
42  
43  
44

45 Clinician 06  
46  
47  
48  
49

50 The experience of having missed a progression due to poor adherence could perpetuate  
51  
52 clinicians fear of missed progression and deter them from wanting to de-escalate active  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 surveillance or transition to watchful waiting because they do not know which patients will  
4  
5 have cancer progression.  
6  
7

8  
9  
10 Fear of litigation/retribution. Clinicians expressed that fear of legal action is in the back of their  
11  
12 mind, but acknowledged that it is rare that they are sued.  
13  
14

15  
16  
17  
18 *“The third barrier is worry over legal stuff although I’ve never heard of someone being sued*  
19  
20 *because of surveillance or not but I think that’s in the back of people’s minds. When I talk to*  
21  
22 *private practice guys they say that”.* Clinician 12  
23  
24

25  
26  
27  
28 The fear of litigation is further amplified by the misalignment of active surveillance and the  
29  
30 natural context of the field and purpose of their work.  
31  
32

33  
34  
35 *“Well there is misalignment of how should I say let’s say perverse incentives for managing*  
36  
37 *people with low grade disease. In other words, physicians get reimbursed for doing*  
38  
39 *something not for doing nothing.”* Clinician 14  
40  
41

## 42 43 44 **DISCUSSION**

45  
46  
47 Our qualitative analysis suggest that surveillance testing for prostate cancer is being decreased  
48  
49 and/or transitioned to watchful waiting in clinical practice. Intentional decisions to decrease  
50  
51 surveillance testing/transition to watchful waiting may consider patients’ age, health, and life  
52  
53 expectancy. These decisions may also take into consideration patients’ values and preferences.  
54  
55  
56

1  
2  
3 Unintentional decisions to decrease surveillance testing/transition to watchful waiting may be  
4  
5 due to missed or cancelled appointments. These missed appointments may be an indicator that  
6  
7 patients are prioritizing their quality of life or ability to work over the management of their  
8  
9 prostate cancer.  
10  
11  
12  
13  
14

15 This study suggests that the issues of age, health, and life expectancy may also play a role in  
16  
17 decisions to decrease surveillance testing or transitioning to watchful waiting, similar to the  
18  
19 decisions to start active surveillance.<sup>21,22</sup> In contrast, a study where clinicians were presented  
20  
21 with scenarios and rank ordered factors that influenced their decision making about starting  
22  
23 active surveillance, found that clinicians used 10-year survival probability, stage, and PSA.<sup>23</sup>  
24  
25  
26  
27  
28  
29

30 A modeling study demonstrated that generally active surveillance had greater quality adjusted  
31  
32 life years than watchful waiting, except among patients diagnosed older than 65 years.<sup>24</sup>  
33  
34

35 Another study found that for men older than 65 years, one biopsy round resulted in a loss of  
36  
37 one quality adjusted life year, likely due to other quality of life outcomes and potential biopsy-  
38  
39 related complications.<sup>9</sup> The University of Toronto stops serial biopsies once a man is 80 years  
40  
41 old and has a life expectancy of less-than five years.<sup>25</sup> However, the consensus statement from  
42  
43 the United Kingdom does state that age as well as other factors need to be considered,  
44  
45 including frailty.<sup>12</sup>  
46  
47  
48  
49  
50  
51

52 As time on active surveillance increases, clinicians' and patients' comfort with active  
53  
54 surveillance and acceptance of the low probability of progression may support them in making  
55  
56  
57  
58  
59  
60

1  
2  
3 the decision to decrease the frequency of surveillance testing/transition to watchful waiting.

4  
5 This finding is consistent with the literature around men who select active surveillance. Patients  
6  
7 and their families who may be more anxious are less likely to choose active surveillance initially  
8  
9 or stop active surveillance for immediate treatment.<sup>21,26</sup> One qualitative study found that men  
10  
11 on active surveillance understood their disease was low-risk and were confident there would be  
12  
13 time for curative treatment if they progressed. These men also had to convince family members  
14  
15 that they were not crazy for having a cancer and not treating it immediately.<sup>27</sup> In a study that  
16  
17 followed men on active surveillance for three years found that over time, men adopted coping  
18  
19 mechanisms and became less anxious about their prostate cancer.<sup>28</sup>  
20  
21  
22  
23  
24  
25  
26  
27

28 The issue of adherence may be associated with the fear of missing the window of curability,  
29  
30 which then in turn may serve as a barrier to decreasing surveillance testing or transitioning to  
31  
32 watchful waiting. Clinicians noted that active surveillance only works if patients show up for the  
33  
34 appointments. However, they recognized that there are practical barriers (e.g., transportation  
35  
36 issues and time off from work) that may contribute to nonadherence to the active surveillance  
37  
38 protocol. In a large cohort of men with grade group 1 prostate cancer, about 24% were lost to  
39  
40 follow-up among men who were not reclassified.<sup>29</sup> However, the increased use of telemedicine  
41  
42 due to the COVID-19 pandemic may help with some of the practical barriers in the future. It  
43  
44 may also help to explore the goals of care at the start of active surveillance and during active  
45  
46 surveillance, so that the clinicians can be aware of what is important to the patient. Another  
47  
48  
49  
50  
51  
52 would be to set the expectation that surveillance testing may decrease over time and that they  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 may transition to watchful waiting in the future. The MUSIC improvement program is taking this  
4  
5 approach to their active surveillance patients.<sup>30</sup>  
6  
7

8  
9  
10 Finally, the fear of litigation may be a barrier to decreasing testing for disease progression and  
11  
12 transitioning to watchful waiting. The fear of litigation is likely related to the fear of missing a  
13  
14 cancer that will become metastatic and its downstream consequences, such as patients and  
15  
16 family members being upset and wanting to sue or submit a complaint. The qualitative study by  
17  
18 Loeb and colleagues found that there are medico-legal considerations when starting active  
19  
20 surveillance because the clinicians felt the need to protect themselves.<sup>13</sup>  
21  
22  
23  
24  
25  
26  
27

28 Although this study provides new information regarding what clinicians consider when making  
29  
30 the decision to decrease the frequency of surveillance monitoring or to transition to watchful  
31  
32 waiting, limitations need to be considered when interpreting the results. The interviews  
33  
34 focused on a variety of issues about active surveillance, such as testing frequency and modality  
35  
36 and decreasing surveillance testing frequency or converting to watchful waiting were only one  
37  
38 area of focus. The sample consisted of clinicians at academic and Veterans Affairs hospitals  
39  
40 representing 11 states. Their perspectives and the patients they treat may not represent the  
41  
42 wider group of clinicians who see and treat men with prostate cancer, such as general  
43  
44 urologists and primary care providers outside of the institutions in this study. Additionally,  
45  
46 clinicians who practice outside the United States may have different experiences because of the  
47  
48 differences in the healthcare system. Some of the interviews were conducted by a female  
49  
50 urologist who is well known among the medical community, which may have introduced  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 response bias. However, this interviewer used open-ended and non-judgmental questioning to  
4 facilitate an open-dialogue. The interviewers did not participate in the analysis process for this  
5  
6 facilitate an open-dialogue. The interviewers did not participate in the analysis process for this  
7  
8 study, limiting the ability to incorporate the insights of the interviewers in the analysis process.  
9  
10 The results and interpretation of this analysis was shared and discussed with the primary study  
11  
12 lead and interviewer.  
13  
14

15  
16  
17 Since the time of the interviews, it is possible that clinical practices regarding de-escalation of  
18 active surveillance and transitioning to watchful waiting have changed. However, the AUA  
19  
20 guidelines on the management of localized prostate cancer does not address the issue of when  
21  
22 or how to de-escalate active surveillance and transition to watchful waiting.<sup>2</sup> The authors aware  
23  
24 of one formal group that has a staged approach to active surveillance, the Michigan Urological  
25  
26 Surgery Initiative.<sup>30</sup>  
27  
28  
29  
30  
31  
32

33  
34  
35 These findings suggested that decreasing surveillance testing frequency or transitioning to  
36 watchful waiting may be happening in certain situations. More research is needed to explore all  
37  
38 the scenarios when clinicians and patients may be amenable to decreasing active surveillance  
39  
40 testing or transitioning to watchful waiting and communication strategies to facilitate this  
41  
42 difficult conversation. These decisions are preference-sensitive and patients' values and  
43  
44 priorities in addition to their health status needs to be considered. Interventions to support  
45  
46 shared decision making, such as patient facing decision aids and encounter based decision aids,  
47  
48 may be helpful to identify patients' values and goals of care in making the decision to transition  
49  
50 to watchful waiting. Clinicians and men need guidance to make thoughtful decisions to  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 decrease surveillance testing or transition to watchful waiting. These guidelines could also  
4  
5 emphasize the need to consider men's preferences in addition to clinical characteristics and  
6  
7 encourage shared decision making.  
8  
9

### 12 **Contributorship statement**

14 Study conception and design: LML; drafting of the study protocol: LML; obtaining of research  
15  
16 funding: LML and SL; acquisition of data: SL. performing of qualitative analysis: LML and NJC  
17  
18 drafting, editing and preparing of the final version of the manuscript: LML, NJC, and SL; Critical  
19  
20 feedback and additional edits: NJC, RJV, KEH, and SL. All authors approved the final manuscript.  
21  
22  
23  
24  
25  
26

### 27 **Funding**

28  
29 Financial Support: This work was supported by a grant from The University of Texas MD  
30  
31 Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment  
32  
33 (Shared Decision Making Collaborative) and a grant from NIH/NCI under award number  
34  
35 P30CA016672 (Clinical Protocol and Data Management, and Shared Decision Making Core). Dr.  
36  
37 Lowenstein was supported by the American Cancer Society under Award Number MRS-18-  
38  
39 225-01-CPPB. Additionally, this work was supported through the Prostate Cancer Foundation,  
40  
41  
42 Feldstein Medical Foundation, Edward Blank and Sharon Cosloy-Blank Family Foundation, the  
43  
44 Gertrude and Louis Feil Family, the New York Department of Health (DOH01-C30697GG-  
45  
46 3450000), The Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center  
47  
48 (P30CA016087), and the NIH (Award Number K07CA178258) to Dr. Loeb. The content is solely  
49  
50  
51 the responsibility of the authors and does not represent the official views of the NIH.  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Data Sharing Statement

Research data are not shared.

## Ethics Statements

### Patient consent for publication

Not required

### Ethics approval

The University of Texas MD Anderson Cancer Center Institutional Review Board (PA17-0642) deemed this protocol as exempt because the study was a secondary analysis of existing data from the parent study. The parent study was approved by NYU (NYU: i14-02147).

## Competing Interests

The authors have no competing interests to report.



## References

1. Siegel DA, O'Neil MA, Richards TB, Dowling NF, Weir HK. *Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001-2017*. 2020.
2. Sanda MG, Chen RC, Crispino T, et al. *Clinically localized prostate cancer: AUA/ASTRO/SUO guideline*. 2017.
3. Bruinsma SM, Bangma CH, Carroll PR, et al. Active surveillance for prostate cancer: a narrative review of clinical guidelines. *Nat Rev Urol*. 2016;13(3):151-167.
4. Hoffman RM, Lobo T, Van Den Eeden SK, et al. Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer. *Med Decis Making*. 2019;39(8):962-974.
5. Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. *Eur Urol*. 2014;65(6):1046-1055.
6. Carroll PR, Parsons JK, Andriole G, et al. NCCN guidelines insights: prostate cancer early detection, version 2.2016. *J Natl Compr Canc Netw*. 2016;14(5):509-519.
7. Lowenstein LM, Basourakos SP, Williams MD, et al. Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned. *Nat Rev Clin Oncol*. 2019;16(3):168-184.
8. Loeb S. Overactive Surveillance: Is "Conservative"; Management for Low-risk Prostate Cancer Too Aggressive? *European Urology*. 2019;76(4):467-468.
9. de Carvalho TM, Heijnsdijk EAM, de Koning HJ. When should active surveillance for prostate cancer stop if no progression is detected? *The Prostate*. 2017;77(9):962-969.

10. Van Hemelrijck M, Garmo H, Lindhagen L, Bratt O, Stattin P, Adolfsson J. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer. *European Urology*. 2017;72(4):534-541.
11. Rajwa P, Sprenkle PC, Leapman MS. When and How Should Active Surveillance for Prostate Cancer be De-Escalated? *Eur Urol Focus*. 2021;7(2):297-300.
12. Merriel SWD, Hetherington L, Seggie A, et al. Best practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement. *BJU International*. 2019;124(1):47-54.
13. Loeb S, Curnyn C, Fagerlin A, et al. Qualitative study on decision-making by prostate cancer physicians during active surveillance. *BJU International*. 2017;120(1):32-39.
14. Sandelowski M. Sample size in qualitative research. *Research in Nursing & Health*. 1995;18(2):179-183.
15. Davison BJ, Goldenberg SL. Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer. *BJU Int*. 2011;108(11):1787-1793.
16. O'Callaghan C, Dryden T, Hyatt A, et al. 'What is this active surveillance thing?' Men's and partners' reactions to treatment decision making for prostate cancer when active surveillance is the recommended treatment option. *Psycho-Oncology*. 2014;23(12):1391-1398.
17. Kazer MW, Bailey Jr DE, Colberg J, Kelly WK, Carroll P. The needs for men undergoing active surveillance (AS) for prostate cancer: results of a focus group study. *Journal of Clinical Nursing*. 2011;20(3-4):581-586.

18. Mishra MV, Bennett M, Vincent A, et al. Identifying Barriers to Patient Acceptance of Active Surveillance: Content Analysis of Online Patient Communications. *PLOS ONE*. 2013;8(9):e68563.
19. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: Bryman A, Burgess RG, eds. *Analyzing Qualitative Data*. London: Routledge; 1994:172-194.
20. Ritchie J, Spencer L, O'Connor W. Carrying out qualitative analysis. In: Ritchie J, Lewis J, eds. *Qualitative Research Practice: A Guide for Social Science Students and Researchers*. London: Sage; 2003:219-262.
21. Pang K, Fitch M, Ouellet V, et al. Describing perspectives of health care professionals on active surveillance for the management of prostate cancer. *BMC Health Serv Res*. 2018;18(1):430-430.
22. Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate Cancer, Version 1.2016. *J Natl Compr Canc Netw*. 2016;14(1):19-30.
23. Clarke MG, Wilson JRM, Kennedy KP, MacDonagh RP. Clinical Judgment Analysis of the Parameters Used by Consultant Urologists in the Management of Prostate Cancer. *Journal of Urology*. 2007;178(1):98-102.
24. Loeb S, Zhou Q, Siebert U, et al. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. *European Urology*. 2017.
25. Garisto JD, Klotz L. Active Surveillance for Prostate Cancer: How to Do It Right. *Oncology (Williston Park)*. 2017;31(5):333-340, 345.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
26. Berger ZD, Yeh JC, Carter HB, Pollack CE. Characteristics and experiences of patients with localized prostate cancer who left an active surveillance program. *Patient*. 2014;7(4):427-436.
27. Volk RJ, McFall SL, Cantor SB, et al. 'It's not like you just had a heart attack': decision-making about active surveillance by men with localized prostate cancer. *Psychooncology*. 2014;23(4):467-472.
28. Dordoni P, Badenchini F, Alvisi MF, et al. How do prostate cancer patients navigate the active surveillance journey? A 3-year longitudinal study. *Supportive Care in Cancer*. 2021;29(2):645-651.
29. Tosoian JJ, Mamawala M, Epstein JI, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. *European Urology*. 2020.
30. Michigan Urological Surgery Initiative. Active Surveillance Roadmap for Management of Men With Favorable-Risk Prostate Cancer. <https://musicurology.com/active-surveillance/>. Accessed June 1, 2021.

## Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist

No	Item	Guide questions/description	Page
<b>Domain 1: Research team and reflexivity</b>			
Personal Characteristics			
1.	Interviewer/facilitator	Which author/s conducted the interview or focus group?	16
2.	Credentials	What were the researcher's credentials? <i>E.g. PhD, MD</i>	1
3.	Occupation	What was their occupation at the time of the study?	1
4.	Gender	Was the researcher male or female?	16
5.	Experience and training	What experience or training did the researcher have?	1
Relationship with participants			
6.	Relationship established	Was a relationship established prior to study commencement?	16
7.	Participant knowledge of the interviewer	What did the participants know about the researcher? <i>e.g. personal goals, reasons for doing the research</i>	16
8.	Interviewer characteristics	What characteristics were reported about the interviewer/facilitator? <i>e.g. Bias, assumptions, reasons and interests in the research topic</i>	16
<b>Domain 2: study design</b>			
Theoretical framework			
9.	Methodological orientation and Theory	What methodological orientation was stated to underpin the study? <i>e.g. grounded theory, discourse analysis, ethnography, phenomenology, content analysis</i>	7

No	Item	Guide questions/description	Page
Participant selection			
10.	Sampling	How were participants selected? <i>e.g. purposive, convenience, consecutive, snowball</i>	8
11.	Method of approach	How were participants approached? <i>e.g. face-to-face, telephone, mail, email</i>	8
12.	Sample size	How many participants were in the study?	8
13.	Non-participation	How many people refused to participate or dropped out? Reasons?	9
Setting			
14.	Setting of data collection	Where was the data collected? <i>e.g. home, clinic, workplace</i>	8
15.	Presence of non-participants	Was anyone else present besides the participants and researchers?	8
16.	Description of sample	What are the important characteristics of the sample? <i>e.g. demographic data, date</i>	7
Data collection			
17.	Interview guide	Were questions, prompts, guides provided by the authors? Was it pilot tested?	8
18.	Repeat interviews	Were repeat interviews carried out? If yes, how many?	8
19.	Audio/visual recording	Did the research use audio or visual recording to collect the data?	8
20.	Field notes	Were field notes made during and/or after the interview or focus group?	NR
21.	Duration	What was the duration of the interviews or focus group?	8

No	Item	Guide questions/description	Page
22.	Data saturation	Was data saturation discussed?	8
23.	Transcripts returned	Were transcripts returned to participants for comment and/or correction?	NR
<b>Domain 3: analysis and findings</b>			
Data analysis			
24.	Number of data coders	How many data coders coded the data?	9
25.	Description of the coding tree	Did authors provide a description of the coding tree?	NR
26.	Derivation of themes	Were themes identified in advance or derived from the data?	9
27.	Software	What software, if applicable, was used to manage the data?	8
28.	Participant checking	Did participants provide feedback on the findings?	NR
Reporting			
29.	Quotations presented	Were participant quotations presented to illustrate the themes / findings? Was each quotation identified? e.g. <i>participant number</i>	10
30.	Data and findings consistent	Was there consistency between the data presented and the findings?	10
31.	Clarity of major themes	Were major themes clearly presented in the findings?	9
32.	Clarity of minor themes	Is there a description of diverse cases or discussion of minor themes?	10